Carrier-free nanodrug based on small molecule drug and sonosensitizer for enhanced the ferroptosis-driven multimodal synergistic therapy of prostate cancer
European Journal of Pharmaceutics and Biopharmaceutics · 2025-03 · 208 · 114656
DOI: 10.1016/j.ejpb.2025.114656 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2025-03. Verfasst von Yao-Lin Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bio-fibers and Eco-Textiles, Institute of Biochemical Engineering, Affiliated Qingdao Central Hospital, College of Materials …. Hauptthemen laut MEDLINE: Ferroptosis, Prostatic Neoplasms, Sorafenib, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: State Key Laboratory of Bio-Fibers and Eco-Textiles, National Key Research and Development Program of China, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Ferroptosis plays a significant role in overcoming the therapeutic resistance of cancer cells. Herein, a carrier-free nanoparticle based on small molecule drug sorafenib (SRF) and sonosensitizer rose bengal (RB) was constructed (named SR NPs) for ferroptosis-driven chemotherapy and sonodynamic synergistic therapy (SDT) of prostate cancer (PCa). SR NPs could be enriched in tumor cells and efficiently inhibit tumor cell proliferation. These nanodrugs could significantly reduce glutathione (GSH) synthesis, and inhibit glutathione peroxidase 4 (GPX4) expression by inhibiting the glutamate/cysteine antiporter system (System Xc-) pathway of ferroptosis. Moreover, SR NPs-mediated ferroptosis significantly improved the amount of reactive oxygen species (ROS) generated by SDT, inhibited cell migration and adhesion, enhanced the accumulation of lipid peroxides (LPO) and augmented chemo-sonodynamic therapy. Notably, in vivo studies demonstrated that SR NPs enhanced tumor accumulation, exhibited good biocompatibility, and showed high anti-tumor efficacy in PC-3 tumor-bearing mice. This work offered a new strategy to enhance the treatment efficacy of prostate cancer (PCa) through ferroptosis-chemotherapy-sonodynamic synergistic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bio-fibers and Eco-Textiles, Institute of Biochemical Engineering, Affiliated Qingdao Central Hospital, College of Materials Science and Engineering, Qingdao University, Qingdao 266071, China.
- State Key Laboratory of Bio-fibers and Eco-Textiles, Institute of Biochemical Engineering, Affiliated Qingdao Central Hospital, College of Materials Science and Engineering, Qingdao University, Qingdao 266071, China. El…
Förderung
- State Key Laboratory of Bio-Fibers and Eco-Textiles
- National Key Research and Development Program of China
- Shandong Province Natural Science Foundation
- Qingdao University
Zitieren
APA
Wu, Y. L., Zhao, R. R., Wu, X., Liu, C. L., & Liu, C. Z. (2025). Carrier-free nanodrug based on small molecule drug and sonosensitizer for enhanced the ferroptosis-driven multimodal synergistic therapy of prostate cancer. European Journal of Pharmaceutics and Biopharmaceutics, 208, 114656. https://doi.org/10.1016/j.ejpb.2025.114656
Vancouver
Wu YL, Zhao RR, Wu X, Liu CL, Liu CZ. Carrier-free nanodrug based on small molecule drug and sonosensitizer for enhanced the ferroptosis-driven multimodal synergistic therapy of prostate cancer. European Journal of Pharmaceutics and Biopharmaceutics. 2025;208:114656. doi:10.1016/j.ejpb.2025.114656
BibTeX
@article{Wu2025,
author = {Wu, Yao-Lin and Zhao, Rui-Rui and Wu, Xiao and Liu, Chun-Lei and Liu, Chun-Zhao},
title = {Carrier-free nanodrug based on small molecule drug and sonosensitizer for enhanced the ferroptosis-driven multimodal synergistic therapy of prostate cancer},
journal = {European Journal of Pharmaceutics and Biopharmaceutics},
year = {2025},
volume = {208},
pages = {114656},
doi = {10.1016/j.ejpb.2025.114656}
}
EUVIMED